The Outpatient Prospective Payment System (OPPS) proposed rule has come out! It will take time to read and digest so details will follow. At first glance, there are no changes to Cellular Tissue Product /skin substitute payment, which remain under package pricing in this site of care. Of note, “skin substitutes” are considered medical supplies for payment purposes. Stay tuned for more information as the proposed rule is evaluated.
Here is a link to the CMS fact sheet.
Submit the form below to receive email alerts when Intellicure publishes a new blog post! This information will not be shared.
You May Also Like …
If practitioners encounter denials by auditors based on the use of note templates, they should probably seek legal counsel.
Hospitals are facing shortages of IV fluids following Hurricane Helene’s damage to Baxter International’s North Cove manufacturing site in Marion, N.C.
Check your scores soon as they will impact your 2025 Medicare payment!